Transformation of Tn7 insertion elements across strains of Vibrio fischeri Authors: Andrew G. Cecere, Chris Muriel-Mundo, Derek J. Fisher, Tim I. Miyashiro, Claudia Isabella Pogoreutz, Claudia Isabella Pogoreutz, Claudia Isabella Pogoreutz Published: 2025 ABSTRACT Animals typically form symbiotic relationships with bacteria that contribute to their physiology and behaviors. The ability to genetically modify these bacterial symbionts is important for investigating the molecular mechanisms that promote symbiosis establishment and maintenance. However, the molecular tools developed for laboratory-adapted strains may fail when applied to non-canonical strains. Here, we report a method to expand the use of Tn7 site-specific transposon-insertion mutagenesis in Vibrio fischeri, which is the bioluminescent bacterial symbiont of the Hawaiian bobtail squid Euprymna scolopes. In this protocol, the laboratory-adapted strain ES114 is used as a surrogate strain for introducing genetic information into the attTn7 insertion site. Genomic DNA extracted from the resulting strain is used as template for transformation of another strain, in which natural transformation is induced. As a proof of principle, this approach is used to complement an rpoN mutant with an IPTG-inducible rpoN construct in trans. Introduction Vibrio fischeri (aka, Aliivibrio fischeri) is a Gram-negative marine bacterium that is capable of establishing symbiosis with various squid and fish [1]. Of these symbioses, the one V. fischeri forms with the Hawaiian bobtail squid Euprymna scolopes is the best understood [2]. From within a symbiotic light organ, V. fischeri populations produce bioluminescence that enables E. scolopes to disrupt its shadow while swimming in the water column at night [3]. The symbiosis forms in hatchlings, following the acquisition of environmental V. fischeri cells that rapidly colonize the nascent light organ and grow into light-emitting populations. For more than 30 years, researchers have used the genetically manipulatable strain ES114 to investigate the general mechanisms by which V. fischeri colonizes the light organ [4]. However, wild-caught animals feature multiple strains of V. fischeri [5], and recent research efforts have investigated how different strains interact while colonizing the nascent light organ [6]. For example, strain FQ-A001 has a type 6 secretion system (T6SS) that facilitates interference competition among V. fischeri strains in vivo [7]. Notably, this T6SS is not encoded by ES114, indicating that the development of approaches for manipulating the genomes of non-canonical strains are of significance for elucidating the molecular mechanisms underlying the interactions between symbiotic V. fischeri strains. Like most Vibrionaceae spp., V. fischeri encodes for the alternative sigma factor RpoN (aka, σ54), which promotes transcription of genes involved in bioluminescence production, biofilm formation, type 6 secretion, and motility [8–11]. Furthermore, σ54 is necessary for V. fischeri to colonize E. scolopes hatchlings [8,9], highlighting its significant regulatory role during the initial stages of symbiosis establishment. Despite its importance in these cellular processes, rpoN is typically nonessential for growth in standard laboratory medium, which has made it a useful control for testing new techniques [12]. Of relevance to the protocol described here, rpoN mutants are amotile due to their inability to activate transcription of flagellar biosynthesis genes [13], thereby permitting simple motility assays to distinguish between wild-type and rpoN alleles. Tn7 is a transposon that inserts into a specific site within the chromosome, known as attTn7 (3’ to the glmS terminator), of many bacterial species including V. fischeri [14,15], which has led to an efficient way to introduce genetic information into the chromosome of a strain without affecting its fitness. Unlike most plasmids, Tn7 chromosomal insertions are stable without selection, thereby eliminating the need to introduce antibiotics in other assays, e.g., squid-colonization assays [16]. This method has proven valuable for experiments designed to test for genetic complementation during studies of ES114 [17,18]. Tn7 insertions have also facilitated competition assays, in which strains can be distinguished by the marker(s) inserted at the Tn7 site [17]. Like many taxa within the Vibrionaceae family, V. fischeri is capable of natural transformation, which describes the ability of a bacterium to incorporate exogenous DNA into its genome [19]. In V. fischeri, this process is controlled by environmental and genetic factors, and investigations of these factors have led to the development of molecular tools to enhance the rates of natural transformation. For instance, pLosTfoX is a plasmid that overexpresses the TfoX regulator that promotes transcription of genes that facilitate natural transformation [20]. The goal of the protocol described here is to use pLosTfoX-dependent natural transformation to introduce genetic elements associated with the Tn7-insertion site of one V. fischeri strain into another. Consequently, this protocol has the potential to overcome technical barriers for inserting genetic content into the Tn7 site of strains recalcitrant to standard transposition approaches. Conditions that may limit the utility of this protocol include the necessity for homology associated with the Tn7 site between strains and the introduction of additional genetic information linked to the Tn7 site by homologous recombination. Materials and methods The protocol described in this peer-reviewed article is published on protocols.io DOI: dx.doi.org/10.17504/protocols.io.kqdg31k11l25/v1 (S1 File). Media and growth conditions V. fischeri strains (Table 1) were grown aerobically in LBS medium [1% (wt/vol) tryptone, 0.5% (wt/vol) yeast extract, 2% (wt/vol) NaCl, 50 mM Tris–HCl (pH 7.5)]. When appropriate, LBS was supplemented with chloramphenicol at a final concentration of 2.5 μg ml-1 and/or erythromycin (Erm) at a final concentration of 5 μg ml-1. 10.1371/journal.pone.0338632.t001Table 1Bacterial strains and plasmids used in this study.StrainGenotypeSourceES114Wild-type symbiotic V. fischeri strain[21]FQ-A001Wild-type symbiotic V. fischeri strain[22]TIM313ES114 Tn7::erm[17]KRG003ES114 ΔrpoN[9]CAM001ES114 ΔrpoN Tn7::[lacIq Ptrc::rpoN erm]This studyAGC020FQ-A001 Tn7::ermThis studyAGC028FQ-A001 Tn7::ermThis studyAGC029FQ-A001 Tn7::ermThis studyAGC030FQ-A001 Tn7::ermThis studyKRG006FQ-A001 ΔrpoN::erm[9]KRG007FQ-A001 ΔrpoN[9]AGC034FQ-A001 ΔrpoN Tn7::ermThis studyAGC038FQ-A001 ΔrpoN Tn7::[lacIq Ptrc::rpoN erm]This study Plasmid Genotype Source pLosTfoXpEVS79 with tfoX cat[20]pEVS107mini-Tn7; mob; erm kan[14]pEVS104R6Kori RP4 oriT trb tra kan[23]pUX-BF13R6Kori tns bla[24]pTM214lacIq Ptrc::mCherry[17]pTM318pEVS107 lacIq Ptrc::mCherry[25]pCAM003lacIq Ptrc::rpoNThis studypCAM004pEVS107 lacIq Ptrc::rpoNThis study Bacterial strains and plasmids used in this study. Tn7 integration assay Chromosomal integration at the attTn7 site in V. fischeri was performed as previously reported using mini-Tn7 delivery plasmids derived from pEVS107, which carries an erythromycin resistance marker (ermR) [14]. To initiate transposition, 0.1-mL cultures of E. coli donor strains harboring the pEVS107-derived plasmid, the helper plasmid pEVS104, and the transposase-encoding plasmid pUX-BF13 were washed in LBS and then combined with the V. fischeri recipient strain in a tetra-parental mating mixture. The mixture was spotted onto LBS agar and incubated at 28 °C for approximately 20 hours. Agar plugs with the mating mixtures were excised using flame-sterilized forceps, resuspended in 1 mL of LBS, and vortexed for 10 seconds. To select for Tn7 integrants, 0.2 mL of the resuspension was plated onto LBS agar supplemented with erythromycin (LBS-erm) and incubated at 28°C. Together, the higher salt concentration of LBS and lower temperature promote the growth of V. fischeri over E. coli. To quantify total viable cells, the remaining suspension was serially diluted 10-fold to 10 ⁻ ⁷, and 0.1 mL aliquots from the 10 ⁻ ⁵ to 10 ⁻ ⁷ dilutions were plated onto LBS agar. Integration frequency was calculated as the ratio of ermR colony-forming units (CFU) to total CFU. Molecular Biology In this protocol, DNA templates for pLosTfoX-dependent natural transformation consisted of either purified PCR products or genomic DNA. For the PCR product, a 3.5-kb amplicon featuring the Tn7::erm region with 0.5-kb flanking homology was amplified from TIM313 genomic DNA by PCR using PFU Ultra Polymerase (Agilent) and primers ES_Tn7-NT-u1 & -l1 (Table 2). The PCR product was purified using the E.Z.N.A. Cycle Pure Kit (Omega Bio-tek, Inc., Norcross, GA, USA). 10.1371/journal.pone.0338632.t002Table 2Primers used in this study.Primer nameSequence (5’ → 3’)Tn7::erm PCRES_Tn7-NT-u1GCTAAACACAGTATGATTCCTTTCES_Tn7-NT-l1GGCATTAGGTAAACAACAAAATCGrpoN::erm PCRFQ_rpoN Del Up FCCTCAAGAAGCTTCTATTTTTAGAFQ_rpoN Del Down RGATAGCTATCCCATTACCTATACCrpoN-Ptrc PCRrpoN-Ptrc-KpnI-u1GGGTACCGGTATCGCTAAATAATGAAArpoN-Ptrc-SalI-l1GGTCGACTAATTAAAGTAAACGCTTACTn7 insertion PCRP1GGAACGGATGTCGATCAGCCTCGTP2CCATTGAAGCTAAAATACTGACTTP3CTAAAGAGGTCCCTAGCGATAAGC Primers used in this study. Plasmid pCAM003 features VF_0387 (rpoN), which encodes σ54 in ES114, downstream of the IPTG-inducible Ptrc promoter. To construct pCAM003, a 1.5-kb fragment containing rpoN was amplified from ES114 genomic DNA by PCR using PFU Ultra Polymerase (Agilent) and primers rpoN-Ptrc-KpnI-u1 & -SalI-l1 and cloned into pCR-Blunt (Invitrogen). Following whole-plasmid sequencing via Plasmidsaurus, the rpoN gene was excised using KpnI/SalI DNA restriction enzymes (New England Biolabs) and subcloned into a KpnI/SalI vector fragment of pTM214 downstream of the Isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible trc promoter (Ptrc). Plasmid pCAM004 contains the IPTG-inducible rpoN construct that can be inserted into the attTn7 site. To construct pCAM004, a 1.7-kb fragment containing rpoN was excised from pCAM003 using KpnI/BsaI and correspondingly subcloned into a 6.8-kb vector fragment of pTM318, which is a Tn7-insertion shuttle vector that contains lacIq Ptrc::mCherry [26], thereby replacing mCherry with rpoN. Strain CAM001 was constructed by inserting the lacIq Ptrc::rpoN erm cassette of pCAM004 into the attTn7 site of KRG003 (ES114 ΔrpoN) using helper plasmids pEVS104 and pUX-BF13. Genome sequencing and analysis To sequence the genome of a strain, genomic DNA was extracted from 0.5 mL LBS starter cultures using the MasterPure Complete DNA and RNA Purification Kit (EpiCentre) and submitted to SeqCenter (Pittsburgh, PA) for Illumina Sequencing. Illumina sequencing libraries were prepared using the tagmentation-based and PCR-based Illumina DNA Prep kit and custom IDT 10-bp unique dual indices (UDI) with a target insert size of 280 bp. No additional DNA fragmentation or size selection steps were performed. Illumina sequencing was performed on an Illumina NovaSeq X Plus sequencer in one or more multiplexed shared-flow-cell runs, producing 2x151-bp paired-end reads. Demultiplexing, quality control and adapter trimming was performed with bcl-convert (v4.2.4). De novo genome assembly was performed using SPAdes genome assembler v3.13.1 and annotated using prokka v1.14.6. The data for this project are available at the Sequence Read Archive (SRA) of NCBI under BioProject accession PRJNA1322440 with BioSample accession numbers SAMN51247791 (TIM313), SAMN51247792 (FQ-A001), SAMN51247793 (AGC020), SAMN51247794 (AGC028), SAMN51247795 (AGC029), and SAMN51247796 (AGC030). Regions of homology involved in natural transformation events at the Tn7 site of FQ-A001-derived strains were determined using Clone Manager 9 Professional Edition. For each genome, the contig containing the glmS region was identified by scanning the contigs for the sequence 5’-GGAACGGATGTCGATCAGCCTCGT-3’. Then for each glmS-containing contig, the Multi-Way Alignment tool was used to align to the corresponding contigs of TIM313 and FQ-A001. Crossover sites for homologous recombination were defined as the SNPs corresponding to TIM313 that were detected in the transformant at the greatest distance from the attTn7 site. Motility assay For each strain, a starter culture was initiated by inoculating LBS medium with an isolated colony and incubating it at 28°C overnight. Starter cultures were diluted 1:100 into fresh LBS medium ± 1 mM IPTG and incubated at 28°C until OD600 ~ 0.2. To initiate the motility assay, a 5-µL volume of the culture was injected into a soft-agar motility plate [0.5% (wt/vol) tryptone, 0.3% (wt/vol) yeast extract, 0.25% (wt/vol) agar, 50% (vol/vol) Instant Ocean] ± 1 mM IPTG and incubated at 28°C. Images of the motility plates were taken over time, and motility rates were calculated from measurements of the motility ring diameter. Statistical analysis Statistical analyses were performed using Prism v. 10.5.0 (GraphPad Software, LLC). Expected results Overview of the pLosTfoX-dependent natural transformation protocol Certain strains of V. fischeri, e.g., FQ-A001, are recalcitrant to approaches that facilitate Tn7 insertion in ES114 (S1 Fig and S1 Data Set). This protocol provides an alternative strategy for introducing genetic information at the Tn7 site into a recipient strain using pLosTfoX-dependent natural transformation. ES114 is used as a surrogate strain to insert genetic information at the Tn7 site. Genomic DNA (gDNA) is then harvested from the resulting strain for use as template for pLosTfoX-dependent natural transformation of the recipient strain. Transformation of FQ-A001 with a Tn7 insertion from ES114 The genomes of ES114 and FQ-A001 exhibit significant homology near the Tn7 insertion site (Fig 1A). TIM313 is an ES114-derived strain with an erm marker inserted at the attTn7 site [17]. A PCR product featuring this Tn7 insertion with ~500 bp of genomic sequence flanking either side (Tn7::erm PCR) can be used as donor DNA for introducing the erm marker into ES114 (Fig 1B and S1 Data Set). Transformation frequency increases 100-fold when TIM313 gDNA is used in place of the PCR product (Fig 1B). FQ-A001 could be transformed with TIM313 gDNA but not the PCR product derived from TIM313. However, FQ-A001 could also be transformed using a PCR product containing the erm marker that had been integrated into the rpoN locus of FQ-A001 (rpoN::erm PCR), suggesting that the use of a PCR product as a template was not the underlying reason for failed transformation with the Tn7::erm cassette. Whole genome sequencing of four FQ-A001-derived strains transformed with TIM313 gDNA showed the presence of the erm marker at the attTn7 site, with homology facilitating homologous recombination ranging from 12–30 kb (Fig 1A and Table 3). 10.1371/journal.pone.0338632.t003Table 3Regions of homology in FQ-A001-derived strains transformed with TIM313 gDNA.Strain nameRange in SJSX01000002aHomology (bp)Upstream attTn7Downstream attTn7AGC0202,353,811−2,366,3341252368045719AGC0282,355,421−2,374,26718846519413652AGC0292,350,193−2,369,70819515104229093AGC0302,353,367−2,383,90130534724823286a SJSX01000002 is the second contig of the FQ-A001 genome. Regions of homology in FQ-A001-derived strains transformed with TIM313 gDNA. a SJSX01000002 is the second contig of the FQ-A001 genome. Expected results. A) Genomic loci of attTn7 sites in FQ-A001 (top) and ES114 (bottom) aligned by progressiveMauve. attTn7 site is outlined by dotted shape. Bars above alignment indicate regions homologous to ES114 in FQ-A001-derived integrants (1 = AGC020, 2 = AGC028, 3 = AGC029, 4 = AGC030). B) Transformation frequency of V. fischeri strains ES114 and FQ-A001 with donor DNA from TIM313 (ES114 Tn7::erm) or KRG006 (FQ-A001 rpoN::erm). Each point represents transformation efficiency (calculated as ermR CFU/total CFU) of one sample (N = 3) and bars represent group geometric mean. Open symbols indicate limit of detection as no ermR CFU were detected. One-way ANOVA detected statistical significance among group geometric means (F4,10 = 91.38, p < 0.0001), with Tukey’s post-hoc test with p-values corrected for multiple comparisons (different letters indicate different statistical groups). Proof of concept: Tn7-based genetic complementation of an rpoN mutant of FQ-A001 As a proof of concept, we tested whether in trans expression of rpoN, which encodes the alternative sigma factor σ54, would restore motility in the amotile ΔrpoN strain of FQ-A001 [9]. pLosTfoX-dependent natural transformation was used to introduce at the attTn7 locus of ΔrpoN either an erm-linked, IPTG-inducible rpoN construct (Ptrc::rpoN) from CAM001 or an erm control marker from TIM313. While ermR transformants positive for Tn7 insertions were recovered for both cases (S2A–B and S3 Figs), only the ΔrpoN-derived strain harboring the Tn7-linked Ptrc::rpoN construct exhibited motility (S2C–D Figs and S1 Data Set), demonstrating genetic complementation of rpoN in FQ-A001. Consequently, one potential application of this protocol is to test for genetic complementation in strains other than ES114. Supporting information Step-by-step protocol, also available on protocols.io. (PDF) Tn7 integration frequency of V. fischeri strains ES114 and FQ-A001. (PDF) Tn7-based genetic complementation of rpoN in FQ-A001. (PDF) Raw image shown in Fig. S2B. (PDF) Values shown in Figs. 1B, S1, and S2D. (XLSX) 3 Nov 2025 Dear Dr. Miyashiro, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Both the expert reviewer active in the field and myself are enthusiastic about this work. Nonetheless, I would like you to ask you to consider the following minor adjustments to increase accessibility of your work to a broader audience: – Brief explanation of the rpoN gene in the introduction for context. – Demonstration of lack of receptiveness of strain FQ-A001 to attTn7 Tn7 insertion – this could tremendously help colleagues in the field facing similar challenges with diverse marine strains. – Include details on selection against donor cells. – Include details on the context of the motility in the context of successful transformation. – A gentle restructuring of results (e.g., introduction of sub-headers). Please submit your revised manuscript by Dec 18 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Claudia Isabella Pogoreutz Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note you have not yet provided a protocols.io PDF version of your protocol and/or a protocols.io DOI. When you submit your revision, please provide a PDF version of your protocol as generated by protocols.io (the file will have the protocols.io logo in the upper right corner of the first page) as a Supporting Information file. The filename should be S1_file.pdf, and you should enter “S1 File” into the Description field. Any additional protocols should be numbered S2, S3, and so on. Please also follow the instructions for Supporting Information captions [https://journals.plos.org/plosone/s/supporting-information#loc-captions]. The title in the caption should read: “Step-by-step protocol, also available on protocols.io.” Please assign your protocol a protocols.io DOI, if you have not already done so, and include the following line in the Materials and Methods section of your manuscript: “The protocol described in this peer-reviewed article is published on protocols.io (https://dx.doi.org/10.17504/protocols.io.[...]) and is included for printing purposes as S1 File.” You should also supply the DOI in the Protocols.io DOI field of the submission form when you submit your revision. If you have not yet uploaded your protocol to protocols.io, you are invited to use the platform’s protocol entry service [https://www.protocols.io/we-enter-protocols] for doing so, at no charge. Through this service, the team at protocols.io will enter your protocol for you and format it in a way that takes advantage of the platform’s features. When submitting your protocol to the protocol entry service please include the customer code PLOS2022 in the Note field and indicate that your protocol is associated with a PLOS ONE Lab Protocol Submission. You should also include the title and manuscript number of your PLOS ONE submission. 3. Thank you for stating in your Funding Statement: “This work was supported by the National Institute of General Medical Sciences Grant R35 GM152259 (to T.I.M.). The funder did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf. 4. Thank you for stating the following in the Acknowledgments Section of your manuscript: “This work was supported by the National Institute of General Medical Sciences Grant R35 GM152259 (to T.I.M.). The funder did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank members of the Miyashiro Lab for helpful discussions regarding the protocol described here.” We note that you have provided funding information that is currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: “This work was supported by the National Institute of General Medical Sciences Grant R35 GM152259 (to T.I.M.). The funder did not and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 5. Thank you for uploading your study's underlying data set. Unfortunately, the repository you have noted in your Data Availability statement does not qualify as an acceptable data repository according to PLOS's standards. At this time, please upload the minimal data set necessary to replicate your study's findings to a stable, public repository (such as figshare or Dryad) and provide us with the relevant URLs, DOIs, or accession numbers that may be used to access these data. For a list of recommended repositories and additional information on PLOS standards for data deposition, please see https://journals.plos.org/plosone/s/recommended-repositories . 6. When completing the data availability statement of the submission form, you indicated that you will make your data available on acceptance. We strongly recommend all authors decide on a data sharing plan before acceptance, as the process can be lengthy and hold up publication timelines. Please note that, though access restrictions are acceptable now, your entire data will need to be made freely accessible if your manuscript is accepted for publication. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If you are unable to adhere to our open data policy, please kindly revise your statement to explain your reasoning and we will seek the editor's input on an exemption. Please be assured that, once you have provided your new statement, the assessment of your exemption will not hold up the peer review process. 7. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 8. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author ?> Reviewer #1: Yes ********** 2. Has the protocol been described in sufficient detail??> To answer this question, please click the link to protocols.io in the Materials and Methods section of the manuscript (if a link has been provided) or consult the step-by-step protocol in the Supporting Information files. Reviewer #1: Partly ********** 3. Does the protocol describe a validated method??> Reviewer #1: Yes ********** 4. If the manuscript contains new data, have the authors made this data fully available??> The PLOS Data policy Reviewer #1: Yes ********** 5. Is the article presented in an intelligible fashion and written in standard English? Reviewer #1: Yes ********** Reviewer #1: This is a great new methodology which will be of value to the scientific community and presents a novel method of transforming otherwise unsuccessfully transformed non canonical strains. The protocol is reasonably well presented but as it is, it requires a great deal of background understanding due to the large amount of undefined jargon and a lack of description of the context of the experiments performed. As such I believe it should be slightly re-written to make it more accessible, and connect the dots of the rationale. - General introduction – I highly recommend introducing the rpoN gene in the introduction to give context to the rest of the paper and the hypothesis and proof of principle testing. I.e. motility assay. - Line 36-39 sentence needs to be re-structured grammatically - 55-56 sentence have led to -the development of - molecular tools to enhance.. Methods - Maybe good to present evidence to support that their strain FQ-A001 isn’t receptive to attTn7 Tn7 insertion, compared to the ES114 WT at this stage of the protocol. In addition, context on why this particular strain was chosen. - T7 integration assay - How did they select against the donor cells harbouring the plasmids which included erm resistance? Was there another selection step to clear the E. coli? - I suggest you define terms like σ54 and Ptrc, KpnI/SalI and explain their relevance. Genome sequencing and analysis - Line 119 – Perhaps the FQ-A001 strain with the Tn7::erm marker needs a new name at this point to avoid confusion? - Was any genome sequencing or analysis or bioinformatics performed to determine if there were enough homologous regions to facilitate their method before attempting the natural transformation. - Line 138-139 – This needs to be rephrase for clarity “Crossover sites for homologous recombination events were called as the SNPs corresponding to TIM313 detected in the transformant furthest from the attTn7 site.”. Motility assay - This requires context. As it is, the reader may find it difficult to understand the purpose of this assay. Please expand on why this assay was performed and how it pertains to confirming the transformation was successful. Expected results (why not just, results?) I believe that the results need to be re-formatted and re-written to be more understandable and clear with the outcomes of this study. Perhaps adding subheadings would be helpful? I think adding part of Figure S2 would help the reader understand the context of the motility assay i.e. S2.D. 191-192 – Should this sentence go at the end of the document? Table 3 – - We need context for what SJSX01000002 is here. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 11 Nov 2025 Please see attached document "2025 PLoS ONE Lab Protocols-Response to Reviewers". Submitted filename: 2025 PLoS ONE Lab Protocols-Response to Reviewers.pdf 25 Nov 2025 Transformation of Tn7 insertion elements across strains of Vibrio fischeri PONE-D-25-51250R1 Dear Dr. Miyashiro, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Claudia Isabella Pogoreutz Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: PONE-D-25-51250R1 PLOS One Dear Dr. Miyashiro, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Prof. Claudia Isabella Pogoreutz Academic Editor PLOS One